Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme

Positive results show that the average weight loss was 12.5 kg (11.8% body weight reduction) with cagrilintide compared to 2.5 kg (2.3%) with placebo, after 68 weeks*1,2Cagrilintide was well-tolerated, with the most common side effects being gastrointestinal; these were mainly transient and mild to moderate in severity1Based on these results, Novo Nordisk will advance cagrilintide into the dedicated RENEW phase 3 clinical programme later this year Bagsværd, Denmark, 16 September 2025 – Novo Nordisk today p ...